Classes | Virtual Medical Academy

Viewing 1180 results

Dermatology

Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment

By :

Prof.Vimal Prajapati

Dermatology

Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights

By :

Prof.Vimal Prajapati

Dermatology

Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights

By :

Prof.Vimal Prajapati

Dermatology

Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate

By :

Prof.Vimal Prajapati

Oncology

Have You Heard? Jaypirca is Now Approved for R/R CLL!

By :

Dr.Tody Eyre

Dermatology

Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

By :

Prof.Vimal Prajapati

Dermatology

Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

By :

Prof.Vimal Prajapati

Dermatology

How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

By :

Lilly Saudi Arabia

Dermatology

Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

By :

Lilly Saudi Arabia

Diabetes

SURMOUNT-5 Clinical Update–Now Published

By :

Carel W Le Roux

Diabetes

Bridging pathophysiology and epidemiology for better understanding of obesity

By :

Dr. Georgios K Dimitriadis

Health administration

مقدمة في إدارة الموارد البشرية في القطاع الصحي

By :

ا. حامد مرزا

About Us

Support

Technical Requirements

VMA Team

Partner

Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment

Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights

Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights

Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate

Have You Heard? Jaypirca is Now Approved for R/R CLL!

Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

SURMOUNT-5 Clinical Update–Now Published

Bridging pathophysiology and epidemiology for better understanding of obesity

مقدمة في إدارة الموارد البشرية في القطاع الصحي

Call Center 920008161

[email protected]